Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES

This announcement is made by Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") at the request of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

With reference to the recent press articles in relation to the manufacturing collaboration between the Group and the Chinese subsidiary of a leading global pharmaceutical company, having made such enquiry with respect to the Company as is reasonable in the circumstances, the Company confirms that such manufacturing collaboration is entered into and will be conducted in the ordinary and usual course of business of the Group. In the ordinary course of its operations, the Group collaborates with various companies across different sectors to advance its business objectives.

The Company is not aware of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
March 12, 2026

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian as independent non-executive Directors.